Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent imexon using dimethyl sulfoxide as solubilising and stabilising agent

Journal of Pharmaceutical Sciences

Volumn 94, Issue 5, 2005, Pages 1101-1114

  Den Brok, Monique W J ^a   Nuijen, Bastiaan ^a   Lutz, Christiane ^b   Opitz, Hans Georg ^b   Beijnen, Jos H ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Wilex Biotechnology GmbH   (Germany)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Calorimetry (DSC); Chemical stability; DMSO; Formulation; Imexon; Lyophilisation; Solubility

Indexed keywords

ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; DIMETHYL SULFOXIDE; IMEXON; IMMUNOMODULATING AGENT; ORGANIC SOLVENT;

AQUEOUS SOLUTION; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FREEZE DRYING; SHELF LIFE; VAPOR PRESSURE;

EID: 20344400666     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20331     Document Type: Article

References (38)

1. Bicker UF. 1975. Immunopharmacological properties of 2-cyanoaziridine derivatives. In Fenichal RS, Chirigos MA, editors. Immune modulation. Agents and their mechanisms. New York: Marcel Dekker. pp 447-473.
2. Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE. 1992. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84:1238-1244.
3. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT. 2001. Induction of mitochondrial changes in myeloma cells by imexon. Blood 97:3544-3551.
4. Iyengar BS, Dorr RT, Remers WA. 2004. Chemical basis for the biological activity of imexon and related cyanoaziridines. J Med Chem 47:218-223.
5. European Pharmacopoeia 2002. 4th edn., Strasbourg: Council of Europe.
6. United States Pharmacopoeia 2000. 24th edn., Rockville, MD: United States Pharmacopoeial Convention, Inc.
7. Boublík T, Fried V, Hála E. 1973. The vapour pressures of pure substances. Amsterdam: Elsevier scientific publishing company.
8. Martin A. 1993. Physical pharmacy, 4 edn., Malvern: Lea & Febiger.
9. Strader ML, Feller SE. 2002. A flexible all-atom model of dimethyl sulfoxide for molecular dynamics simulations. J Phys Chem 106:1074-1080.
10. Dermer OC, Ham GM. 1969. Reaction of aziridines. Ethylenimine and Other Aziridines. New York: Academic Press, Inc. pp 106-314.
11. Jonkman-de Vries JD, Winkelhorst J, Underberg WJM, Henrar REC, Beijnen JH. 1993. A systematic study on the chemical stability of the novel indoloquinone antitumor agent EO9. Int J Pharm 100: 181-188.
12. van Maanen MJ, Brandt AC, Damen JM, Beijnen JH. 1999. Degradation study of thiotepa in aqueous solutions. Int J Pharm 179:55-64.
13. Brewster ME, Simpkins JW, Hora MS, Stern WC, Bodor N. 1989. The potential use of cyclodextrins in parenteral formulations. J Parenter Sci Technol 43:231-240.
14. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85:1017-1025.
15. Brown ME. 1988. Purity determination using DSC. Introduction to Thermal Analysis. Techniques and Applications. New York: Chapman and Hall Ltd. pp 152-162.
16. Pikal MJ, Shah S, Senior D, Lang JE. 1983. Physical chemistry of freeze-drying: Measurement of sublimation rates for frozen aqueous solutions by a microbalance technique. J Pharm Sci 72:635-650.
17. Teagarden DL, Baker DS. 2002. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur J Pharm Sci 15:115-133.
18. Zou Y, Prieb W, Perez-soler R. 1999. Submicron liposome suspensions obtained from preliposome lyophilizates. Patent 5,902,604, United States.
19. Desai UR, Klibanov AM. 1995. Assessing the structural integrity of a lyophilized protein in organic solvents. J Am Chem Soc 117:3940-3945.
20. Stella VJ, Umprayn K, Waugh WN. 1988. Development of parenteral formulations of experimental cytotoxic agents. I. Rhizoxin (NSC-332598). Int J Pharm 43:191-199.
21. Baldi G, Gasco MR, Pattarino F. 1994. Statistical procedures for optimizing the freeze-drying of a model drug in Ter-Butyl alcohol. Eur J Biochem 40:138-141.
22. Wittaya-Areekul S, Nail SL. 1998. Freeze-drying of tert-butyl alcohol/water cosolvent systems: Effects of formulation and process variables on residual solvents. J Pharm Sci 87:491-495.
23. Nuijen B, Bouma M, Henrar REG, Floriano P, Jimeno JM, Talsma H, Kettenes-van den Bosch JJ, Heck AJR, Bult A, Beijnen JH. 2000. Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine. PDA J Pharm Sci Technol 54:193-208.
24. Wittaya-Areekul S, Needham GF, Milton N, Roy ML, Nail SL. 2002. Freeze-drying of tert-butanol/ water cosolvent systems: A case report on formation of a friable freeze-dried powder of tobramycin sulfate. J Pharm Sci 91:1147-1155.
25. Lambert D, Flink J, Karel M. 1973. Volatile transport in frozen aqueous solutions. II. Influence of system parameters. Cryobiology 10: 52-55.
26. Pikal MJ, Roy ML, Shah S. 1984. Mass and heat transfer in vial freeze-drying of pharmaceuticals: role of the vial. J Pharm Sci 73:1224-1237.
27. Tang X, Pikal MJ. 2004. Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharm Res 21:191-200.
28. Handbook of pharmaceutical excipients 2003. 4 edn., London, Chicago: Pharmaceutical press and the American pharmaceutical association.
29. Templeton AC, Placek J, Xu H, Mahajan R, Hunke WA, Reed RA. 2003. Determination of the moisture content of bromobutyl rubber stoppers as a function of processing: Implications for the stability of lyophilized products. PDA J Pharm Sci Technol 57:75-87.
30. Wang Z, Frankel BA, Lambert WJ. 2001. Determination of moisture in rubber stoppers: Effect of Karl Fischer oven temperatures. PDA J Pharm Sci Technol 55:162-170.
31. ICH Steering Committee 1997. ICH Q3C Impurities: Residual solvents. London (CPMP/ICH/2737/99): European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation.
32. Patel SD, Yalkowsky SH. 1987. Development of an intravenous formulation for the antiviral drug 9-(beta-D-arabinofuranosyl)-adenine. J Parenter Sci Technol 41:15-20.
33. Sweetana S, Akers MJ. 1996. Solubility principles and practices for parenteral drug dosage form development. PDA J Pharm Sci Technol 50:330-342.
34. Lee DK, Wang DP. 1999. Formulation development of allopurinol suppositories and injectables. Drug Dev Ind Pharm 25:1205-1208.
35. Davis J, Rowley SD, Santos GW. 1990. Toxicity of autologous bone marrow graft infusion. Prog Clin Biol Res 333:531-540.
36. Shpall EJ, LeMaistre CF, Holland K, Ball E, Jones RB, Saral R, Jacobs C, Heimfeld S, Berenson R, Champlin R. 1997. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 90:4313-4320.
37. Luo KH, Shi YK, Sun Y, Wang QL, Wu GQ, Feng FY, Gui W, Liu HB. 1995. A practical procedure for the cryopreservation of marrow cells intended for autotransplantation. Leuk Lymphoma 17:495-499.
38. Ely A, Lockwood B. 2002. What is the evidence for the safety and efficacy of dimethyl sulfoxide and methylsulfonylmethane in pain relief. The Pharm J 269:685-687.